Alan H. Horwich

Alan H. Horwich's AcademicInfluence.com Rankings

Alan H. Horwich

Philosophy

#6386

World Rank

#9416

Historical Rank

Logic

#3560

World Rank

#4742

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Alan H. Horwich's Degrees

Doctorate Medicine Harvard University

Why Is Alan H. Horwich Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alan H. Horwich's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers (1997) (1180)
Carboplatin/cisplatin (1988) (1123)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (1023)
Multiple newly identified loci associated with prostate cancer susceptibility (2008) (866)
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial (1999) (761)
Testicular germ-cell cancer (2006) (608)
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. (2008) (556)
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array (2012) (550)
Guidelines on Testicular Cancer: 2015 Update. (2015) (525)
Cardiovascular disease as a long-term complication of treatment for testicular cancer. (2003) (517)
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). (2004) (476)
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. (2000) (453)
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. (2007) (435)
Guidelines on testicular cancer. (2005) (428)
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study (2009) (428)
Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. (2005) (420)
Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. (2002) (398)
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. (1992) (389)
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (381)
Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. (1999) (363)
EAU guidelines on testicular cancer: 2011 update. (2011) (344)
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. (1997) (326)
Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. (2003) (324)
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. (2010) (316)
Multiple loci on 8q24 associated with prostate cancer susceptibility (2009) (316)
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. (1996) (313)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. (2012) (300)
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study (2011) (295)
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. (1999) (287)
Craniopharyngioma--a long-term results following limited surgery and radiotherapy. (1993) (281)
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. (2008) (270)
The dose-rate effect in human tumour cells. (1987) (269)
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer (2012) (268)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019) (266)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (263)
Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis (2002) (261)
Fertility after chemotherapy for testicular germ cell cancers. (1997) (261)
Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). (2005) (256)
The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). (1983) (250)
A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. (2005) (243)
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (241)
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. (2001) (240)
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects (2005) (233)
Medium-term outcomes of active surveillance for localised prostate cancer. (2013) (231)
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. (2008) (231)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (221)
Fertility, gonadal and sexual function in survivors of testicular cancer (2005) (211)
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up (2018) (205)
Surveillance following orchidectomy for stage I testicular seminoma. (1992) (196)
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. (2008) (191)
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. (2011) (175)
Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. (1986) (174)
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. (2009) (167)
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. (1992) (164)
Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. (2000) (162)
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. (2001) (151)
Testicular germ cell tumours (2013) (151)
Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. (1998) (150)
Prostate cancer: ESMO Consensus Conference Guidelines 2012. (2013) (144)
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours (1999) (142)
Long‐term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer (2010) (135)
Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). (1985) (135)
Preliminary results of a phase I dose escalation clinical trial using focused ultrasound in the treatment of localised tumours. (1999) (133)
Metastatic nonseminomatous germ cell tumors of the testis (2002) (133)
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. (2013) (131)
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. (2012) (131)
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. (2001) (128)
Managing testicular cancer (2001) (124)
Radiotherapy for stage I seminoma testis: results of treatment and complications. (1986) (121)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (120)
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. (2008) (116)
Early outcomes of active surveillance for localized prostate cancer (2005) (112)
Optic gliomas: radiation therapy and prognosis. (1985) (110)
The Biological Basis of Radiotherapy (1989) (109)
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials (2004) (109)
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. (2019) (108)
Treatment results and prognostic factors in 101 men treated for squamous carcinoma of the penis. (1997) (107)
Evaluation of adjuvant psychological therapy in patients with testicular cancer: randomised controlled trial (1998) (106)
PROGNOSTIC FACTORS IN ADVANCED NON-SEMINOMATOUS GERM-CELL TESTICULAR TUMOURS: RESULTS OF A MULTICENTRE STUDY Report from the Medical Research Council Working Party on Testicular Tumours (1985) (106)
Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. (1991) (104)
Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. (1993) (104)
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. (2002) (104)
Orchidectomy alone for stage I seminoma of the testis (1990) (102)
Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone. (1990) (99)
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. (2007) (99)
Treatment of nondysgerminomatous ovarian germ cell tumors (1999) (98)
Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (96)
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. (2001) (95)
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. (2012) (95)
Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. (1989) (94)
Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. (1988) (92)
A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma (2000) (91)
Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. (1997) (89)
Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse (2008) (88)
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact (2011) (86)
Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. (2001) (86)
Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. (1991) (86)
Technological advances in radiotherapy for the treatment of localised prostate cancer. (2005) (83)
Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. (1991) (82)
Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. (2009) (81)
Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. (1995) (81)
Late recurrence in 1263 men with testicular germ cell tumors (2002) (81)
Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. (2006) (81)
Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma (2013) (81)
The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. (2007) (79)
Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. (1997) (79)
Adaptive-predictive organ localization using cone-beam computed tomography for improved accuracy in external beam radiotherapy for bladder cancer. (2011) (79)
Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. (1989) (78)
Mortality and incidence of second cancers following treatment for testicular cancer (2007) (78)
Molecular cytogenetic analysis of adult testicular germ cell tumours and identification of regions of consensus copy number change. (1998) (78)
Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2009) (77)
Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. (1994) (76)
Prostate‐specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time (2009) (75)
Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer (2007) (74)
Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (73)
Orchiectomy alone for Stage I testicular non-seminoma. A progress report on the Royal Marsden Hospital study. (1983) (72)
2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. (2012) (72)
Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? (2003) (70)
A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. (2005) (69)
Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation. (2013) (66)
'JEB'--a carboplatin based regimen for malignant germ cell tumours in children. (1990) (65)
Residual mass following chemotherapy of seminoma. (1997) (64)
The late effects of cis-platinum on renal function. (1989) (62)
Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. (1997) (60)
Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (60)
Predictors of histological disease progression in untreated, localized prostate cancer. (2007) (60)
Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience. (2010) (59)
Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis. (1987) (59)
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. (2015) (57)
Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. (2003) (56)
Whole‐body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer (2009) (55)
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. (1997) (55)
Programmed cell death in response to chemotherapeutic agents in human germ cell tumour lines. (1995) (55)
Surveillance after orchiectomy for stage I seminoma of the testis. (1987) (54)
Non-Hodgkin's lymphoma presenting with extradural spinal cord compression: functional outcome and survival. (1991) (54)
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone (2002) (53)
Mortality and cancer incidence following radiotherapy for seminoma of the testis. (1994) (52)
A pilot study of intermittent androgen deprivation in advanced prostate cancer. (1998) (51)
The activity of single-agent carboplatin in advanced seminoma. (1992) (51)
Second primary breast cancer after Hodgkin's disease (2004) (50)
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma (2005) (50)
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (2019) (49)
A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069. (1986) (48)
Assessing intra-fractional bladder motion using cine-MRI as initial methodology for Predictive Organ Localization (POLO) in radiotherapy for bladder cancer. (2007) (47)
EAU Guidelines on testicular cancer, 2011 update (2012) (47)
Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. (1995) (47)
Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (47)
"Bad risk" non-Hodgkin lymphomas. (1983) (47)
Microsatellite instability in human testicular germ cell tumours. (1995) (45)
The utility of lactate dehydrogenase in the follow‐up of testicular germ cell tumours (2007) (45)
Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment (2017) (45)
Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. (2010) (45)
The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer (2010) (45)
Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance (2009) (44)
Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer. (2016) (44)
Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. (1986) (44)
Hypofractionated radiotherapy for patients with carcinoma of the bladder. (1999) (44)
The effects of single dose oral hydralazine on blood flow through human lung tumours. (1990) (43)
Management of the contralateral testis in patients with testicular germ cell cancer. (1990) (42)
A feasibility study of using gold seeds as fiducial markers for bladder localization during radical radiotherapy. (2007) (42)
Surveillance in stage I seminoma patients: a long-term assessment. (2010) (42)
Testicular cancer : investigation and management (1991) (42)
Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer (2006) (42)
Salvage radiotherapy in recurrent Hodgkin's disease. (1992) (42)
The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. (1992) (42)
Postchemotherapy Residual Masses in Germ Cell Tumor Patients. Content, Clinical Features, and Prognosis (1999) (41)
Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study. (2008) (41)
Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. (2001) (41)
Imaging metastatic testicular germ cell tumours with18FDG positron emission tomography: prospects for detection and management (1995) (39)
Extragonadal germ cell tumors: relation to testicular neoplasia and management options (2003) (39)
The role of 18F-FDG PET/CT in the management of testicular cancers (2015) (39)
Conformal radiotherapy of the pelvis: assessment of acute toxicity. (1993) (39)
[EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. (2012) (39)
Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. (1995) (39)
Detection of occult spinal cord compression with magnetic resonance imaging of the spine. (2007) (39)
Placental alkaline phosphatase as a tumour marker in seminoma using the H17 E2 monoclonal antibody assay. (1985) (39)
Primary malignant mediastinal germ cell tumours: improved prognosis with platinum-based chemotherapy and surgery. (1993) (39)
Thoracic metastasectomy for germ cell tumours: long term survival and prognostic factors. (1998) (39)
Persistent carcinoma in situ of the testis after chemotherapy for advanced testicular germ cell tumours. (1990) (38)
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer (1999) (38)
cis-Diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumours: a preliminary report. (1985) (37)
Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy (2006) (37)
An analysis of prognostic factors in early stage Hodgkin's disease. (1986) (37)
The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer (2000) (37)
Inguinal and iliac lymph node involvement in germ cell tumours of the testis: implications for radiological investigation and for therapy. (1991) (36)
The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors (2000) (36)
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948) (2005) (35)
Prostate cancer segregation analyses using 4390 families from UK and Australian population‐based studies (2009) (34)
Influence of delay in diagnosis on prognosis in testicular teratoma. (1989) (34)
Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors (2013) (34)
Clinical presentation as a predictor of laparotomy findings in supradiaphragmatic stage I and II Hodgkin's disease. (1986) (34)
Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma. (1985) (33)
Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. (2013) (32)
Germ cell tumour chemotherapy. (1989) (32)
Circulating lymphoma cells in patients with B & T non-Hodgkin's lymphoma detected by immunoglobulin and T-cell receptor gene rearrangement. (1987) (31)
Bulky mediastinal Hodgkin's disease management and prognosis (1984) (31)
Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours. (1989) (30)
Diethylstilbestrol in castration‐resistant prostate cancer (2012) (30)
Serum tumour marker regression rate following chemotherapy for malignant teratoma. (1984) (30)
Risk of premature menopause after treatment for Hodgkin's lymphoma. (2014) (29)
Tumours of the prostate. (2001) (28)
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. (2010) (28)
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. (2012) (28)
Patterns of care in the management of seminoma stage I: results from a European survey (2012) (27)
Oncology : a multidisciplinary textbook (1995) (27)
Risk factors for carcinoma in situ of the contralateral testis in patients with testicular cancer. An interim report. (1993) (27)
Markers and management of germ-cell tumours of the testes (1998) (27)
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone (2006) (27)
The association of germ cell tumours of the testis with sarcoid-like processes. (1992) (27)
Cost versus benefit in non-surgical management of patients with cancer. (1988) (27)
Prospective study of factors predicting adherence to medical advice in men with testicular cancer. (2009) (26)
Second malignancies and Hodgkin's disease--the Royal Marsden Hospital experience. (1988) (26)
Ejaculatory dysfunction after retroperitoneal lymphadenectomy. (1993) (26)
Accelerated chemotherapy for poor prognosis germ cell tumours. (1994) (25)
Evaluating inter-fractional changes in volume and position during bladder radiotherapy and the effect of volume limitation as a method of reducing the internal margin of the planning target volume. (2008) (24)
Treating IIA/B seminoma with combination carboplatin and radiotherapy. (2009) (24)
Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer? (2009) (24)
Radiotherapy in stage I seminoma of the testis. (2004) (24)
Prognostic factors for survival in advanced non-seminomatous germ cell tumours: A study by the Medical Research Council Testicular Tumours Working Party (1990) (24)
The management of advanced testicular teratoma. (1988) (24)
DOXORUBICIN, RADIOTHERAPY, AND ŒSOPHAGEAL STRICTURE (1975) (24)
Clinical and technical aspects of conformal therapy (1993) (24)
Prognosis of testicular teratoma differentiated. (1994) (23)
Identification of new genetic risk factors for prostate cancer. (2009) (23)
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. (2019) (23)
The management of paratesticular rhabdomyosarcoma. (1989) (22)
Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy (2000) (22)
Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease. (1994) (22)
Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up (2013) (22)
Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2009) (22)
The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy. (1990) (21)
Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. (1997) (21)
Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer. (2006) (21)
Salvage therapy of germ cell tumours. (1995) (21)
Frequency of screening magnetic resonance imaging to detect occult spinal cord compromise and to prevent neurological deficit in metastatic castration-resistant prostate cancer. (2010) (20)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2016) (20)
Prognostic factors in metastatic germ cell tumors. (1990) (20)
Primary Adult Renal Ewing's Sarcoma: A Rare Entity (2009) (20)
Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. (2005) (20)
Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer (2002) (20)
Molecular Cytogenetic Analysis of Adult Testicular Germ Cell Tumours and Identification of Regions of Consensus Copy Number Change (1998) (19)
Evaluation by magnetic resonance imaging of the inferior vena cava in patients with non-seminomatous germ cell tumours of the testis metastatic to the retroperitoneum. (1997) (19)
Carboplatin dose in combination chemotherapy for testicular cancer. (1991) (19)
Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013 (2017) (19)
Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma (2004) (18)
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder (2015) (17)
Chemotherapy and radiotherapy for advanced testicular nonseminoma (1983) (17)
Prostate‐specific antigen velocity in untreated, localized prostate cancer (2007) (17)
Challenges in treating patients with Down's syndrome and testicular cancer with chemotherapy and radiotherapy: The Royal Marsden experience. (2007) (17)
Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial. (2008) (17)
Spermatocytic seminoma in a maldescended testis. (1993) (17)
Sarcoid-like lymphadenopathy in malignant teratoma. (1983) (16)
Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy. (2006) (16)
Combined single course carboplatin with radiotherapy in treatment of stage IIA,B seminoma--a preliminary report. (1994) (16)
Initial chemotherapy for stage II testicular non-seminoma (2004) (16)
Systemic treatment for prostate cancer. (2006) (16)
Use of carboplatin in germ cell tumors of the testis. (1992) (15)
Conformal radiotherapy at the Royal Marsden Hospital (UK). (1994) (15)
The management of early‐stage aggressive non‐Hodgkin's lymphoma (1988) (15)
Stage III Hodgkin's disease--long-term results following chemotherapy, radiotherapy and combined modality therapy. (1989) (15)
Intracardiac metastases from germ cell tumours--an unusual but important site of metastasis. (1992) (15)
The effect of carboplatin on renal function in patients with metastatic germ cell tumours. (1991) (15)
Prostate cancer management. (2004) (15)
Radiotherapy results in laparotomy-staged Hodgkin's disease. (1988) (15)
The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time--I. Theoretical basis and practical application. (1990) (14)
Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours? (1992) (14)
Changing patterns of relapse in Hodgkin's disease. (1989) (13)
Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244 (2008) (13)
Questions in the management of seminoma. (1990) (13)
Severe lung toxicity with a weekly low dose chemotherapy regimen in patients with non‐Hodgkin's lymphoma (1988) (13)
Outcome of early detection and radiotherapy for occult spinal cord compression. (2007) (13)
Update on management of seminoma (2010) (13)
Case report: Malignant teratoma presenting with an adrenal mass (1987) (13)
Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL) (2007) (12)
Bleomycin and scuba diving: where is the harm? (2007) (12)
Embryonal rhabdomyosarcoma arising in a germ cell tumour. (1994) (12)
Primary chemotherapy after orchidectomy for stage I and II nonseminoma. (1998) (12)
Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin. (1987) (12)
Chemotherapy and radiotherapy for advanced testicular non-seminoma. I. The influence of sequence and timing of drugs and radiation on the appearance of normal tissue damage. (1983) (12)
Optimal field size in adjuvant radiotherapy (XRT) of stage I seminoma - a randomised trial (1996) (12)
Increasing the dose intensity of chemotherapy in poor-prognosis metastatic non-seminoma. (1993) (12)
Current opinion on adjuvant and salvage treatment after radical prostatectomy. (2004) (12)
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder (2016) (12)
Combined radiotherapy and chemotherapy in clinical oncology (1992) (11)
Seminal analysis after orchiectomy in stage I teratoma. (1988) (11)
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study. (1997) (11)
The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy +/- neoadjuvant androgen deprivation. (2004) (11)
Familial predisposition to both male and female germ cell tumours? (1996) (11)
Treatment of seminoma. (1992) (11)
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma (2015) (11)
Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillance (2010) (11)
Infradiaphragmatic Hodgkin's disease. (1992) (10)
Prognosis following chemotherapy for metastatic malignant teratoma. (1987) (10)
GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma (2014) (10)
Surveillance after orchidectomy for clinical stage I germ-cell tumours of the testis. (1988) (10)
An analysis of surveillance for stage I combined teratoma--seminoma of the testis. (1996) (10)
Spermatocytic seminoma: a clinicopathological review of ten patients. (1996) (10)
Treatment of Cancer, 3rd edn (1997) (9)
Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy. (2010) (9)
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array (2016) (9)
Brief Report: Phase II Multicenter Study of Temozolomide in Patients with Cisplatin-Resistant Germ Cell Tumors (2011) (9)
Peripheral blood involvement in non-Hodgkin's lymphoma detected by clonal gene rearrangement as a biological prognostic marker. (1994) (8)
Haematological toxicity of radiotherapy following high-dose chemotherapy and autologous bone marrow transplantation in patients with recurrent Hodgkin's disease. (1994) (8)
Hodgkin's Disease of the Epididymis and Testis (1989) (8)
Current controversies in the management of testicular cancer (1991) (8)
Long-term follow-up of unresected residual masses following platinum based chemotherapy for metastatic non-seminoma of the testis (MRC Study TE16): a preliminary report (1998) (8)
Prostate Radiotherapy: Evaluating the Effect of Bladder and Rectal Changes on Prostate Movement - A CT Study (2006) (8)
Minimizing toxicity in early-stage testicular cancer treatment (2012) (7)
Prognostic factors in patients (pts) with advanced metastatic seminoma (SEM) treated with either single agent carboplatin (CP) or cisplatin-based (DDP) combination chemotherapy (CTX): a meta-analysis of prospective European trials. (2002) (7)
The impact of hydronephrosis on renal function in patients treated with cisplatin‐based chemotherapy for metastatic nonseminomatous germ cell tumors (1988) (7)
Rare Tumors of the Testis and Paratesticular Tissues (2006) (7)
The biological basis of radiotherapy. Second edition (1989) (6)
The future of radiotherapy. (1990) (6)
UROLOGY AND THE TNM CLASSIFICATION (1988) (6)
Neoadjuvant chemotherapy for invasive bladder cancer (2005) (6)
Phase I dose-escalated image-guided adaptive bladder radiotherapy study: Results of first dose cohort (68Gy). (2014) (6)
Clinical implications of introducing a new PSA assay (2008) (6)
Current issues in the management of clinical stage I testicular teratoma. (1993) (6)
The Staging and Treatment of Testicular Cancer: Management of Stage I Disease (1989) (6)
Uptake of technetium-99m hexamethylpropylene amine oxime labelled white cells in lymph nodes involved in non-Hodgkin's lymphoma (1995) (6)
Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population. (2008) (6)
Cancer Research Campaign review of radiobiology research. (1993) (6)
A randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped progressive metastatic prostate cancer (1998) (5)
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. (2020) (5)
Baseline Urinary Phytoestrogen Levels and the Natural History of Untreated, Localised Prostate Cancer in a British Population (2008) (5)
Breast Cancer after Radiotherapy for Hodgkin's Disease (1998) (5)
Stage I Seminoma (2006) (5)
Counselling is not appropriate for all patients with cancer (1999) (5)
Sites of relapse in seminoma treated with single agent carboplatin chemotherapy: implications for further management. (1992) (5)
SEMEN CRYOPRESERVATION FOR PATIENTS SURVIVING MALIGNANT DISEASE: IMPLICATIONS OF PROPOSED LEGISLATION (1988) (5)
Radical radiotherapy for carcinoma of the anal canal. (1990) (5)
Management of early prostate cancer. (2002) (5)
Stage I seminoma and carboplatin risks. (2007) (5)
Populations of Exposure to Low Levels of Ionizing Radiations (Committee on the Biological Effects of Ionizing Radiations (1986) (4)
Circulating tumor markers. (2008) (4)
Residual masses post-chemotherapy for germ cell tumour: content, clinical features and prognosis (1998) (4)
The familial influence on bilateral testicular germ cell cancer: Medical Research Council study TER2. (2006) (4)
Corrigendum to: "European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer (2008) (4)
The ESMO guideline strategy: an identity statement and reflections on improvement. (2015) (4)
2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residuals: A retrospective validation of the SEMPET trial. (2010) (4)
Radiotherapy update. (1992) (4)
The management of early Hodgkin's disease. (1990) (4)
A randomised trial of 30Gy vs 20Gy in the adjuvant treatment of stage I testicular seminoma (MRC TE18, EORTC 30942, ISRCTN 8525328) (2005) (4)
A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC. (2013) (4)
Small-Cell Carcinoma of the Prostate (1997) (4)
Imaging properties of polydioxanone and titanium ligating clips following para-aortic lymphadenectomy for testicular cancer. (1991) (4)
Current status of chemotherapy in advanced seminoma. (1997) (4)
Malignant teratoma presenting with an adrenal mass. (1987) (4)
Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2007) (3)
Long-term outcome of high-dose chemotherapy and autologous stem cell transplantation in relapsed/refractory Hodgkin's disease: A cohort of 199 pts from Royal Marsden Hospital. (2006) (3)
Metastatic non-seminomatous germ cell tumour and dermatomyositis. (1990) (3)
A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs). (2011) (3)
Appendix 9: Testicular seminoma and non-seminoma: eUpdate published online 29 June 2017 (www.esmo.org/Guidelines/Genitourinary-Cancers). (2017) (3)
Carboplatin-based chemotherapy in good prognosis metastatic non seminoma of the testis (NSGCT): An interim report of an MRC/EORTC randomised trial (1993) (3)
Management of patients with non-seminomatous germ cell tumours stage I. (1990) (3)
The role of computed tomography of the brain in the investigation of breast cancer patients with suspected intracranial metastases. (1981) (3)
Assessment of combination treatment with gemcitabine, cisplatin, and methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell lymphoma. (2010) (2)
Radiation Resistance and the Dose-Rate Effect: Experimental (1988) (2)
SECONDARY LEUKAEMIA IN HODGKIN'S DISEASE (1986) (2)
Minimal benefit from radiotherapy (RT) after chemotherapy (CT) for metastatic seminoma: analysis of Medical Research Council (MRC-UK) database (1997) (2)
Intensity Modulated Radiotherapy (IMRT) Can Safely Deliver 60 Gy to the Pelvic Lymph Node Regions in Patients with Prostate Cancer: Report of a Phase I Dose Escalation Study (2009) (2)
Carboplatin (Jm8), Vp16, Bleomycin - (Jeb) in Children with Malignant Germ-Cell Tumors (Mgct) (1987) (2)
Accelerated chemotherapy for germ cell cancer. (2014) (2)
Primary chemotherapy: how does it compare with surgery? (1996) (2)
Chemotherapy of seminoma. (1993) (2)
Lymphocyte-predominant Hodgkin's lymphoma. (2010) (2)
Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial. (2004) (2)
Late CT surveillance in nonseminoma germ cell tumors (NSGCT). (2011) (2)
Current controversies in the treatment of testicular cancer. (1991) (1)
Erratum: Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder (British Journal of Cancer (2015) 112, (1626-1635)) doi: 10.1038/bjc.2015.109 (2016) (1)
Organ preservation of bladder cancer (1993) (1)
Dose Escalated Adaptive Bladder Radiotherapy: Clinical Outcomes of a Phase I Study (2020) (1)
Haematological morbidity in patients with Hodgkin's disease treated with radiotherapy following autologous bone marrow transplantation (1993) (1)
Evaluating the Impact of Volume Limitation as a Method of Reducing the Internal Margin of the PTV in Bladder Radiotherapy (2007) (1)
Testicular cancer. (1989) (1)
The incidence of germline p53 mutations in 53 Li-Fraumeni-like families and in individuals with multiple primary tumors (1994) (1)
Gemcitabine, cisplatin and methylprednisolone (GEM-P) in patients with T-cell lymphoma: Results from The Royal Marsden Hospital. (2006) (1)
Reply to the letter to the editor 'Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy' by Tannock et al. (2016) (1)
Can bleomycin toxicity in the treatment of testis cancer be batch related? (2005) (1)
Technetium-99m HMPAO andSPECTintheassessment ofblood flowinhumanlungtumours (1989) (1)
Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013 (2014) (1)
The Role of Surveillance versus Adjuvant Treatment in Stage I Germ Cell Tumors: Outcomes and Challenges. (2015) (1)
Quantitating risk of contralateral testicular carcinoma in situ (CIS) in patients with testicular cancer an MRC study (1996) (1)
497 oral PHASE III PILOT STUDY OF DOSE ESCALATION USING CON-FORMAL RADIOTHERAPY IN PROSTATE CANCER: LONG TERM FOLLOW UP (2011) (1)
Associated With Primary Mediastinal Nonsemino-matous Germ Cell Tumors (1999) (1)
Proliferative Fraction in Human Bladder Carcinoma Measured by Ki-67 Antibody Labelling—Its Potential Clinical Use (1989) (1)
Accelerated chemotherapy in the treatment of urothelial cancer. (2001) (1)
Multidisciplinary treatment of cancer: radiotherapy (2004) (1)
Carboplatin in the combination chemotherapy of non-seminomatous germ cell tumours. (1996) (1)
Book Review Bladder Cancer: Biology, diagnosis, and management Edited by Konstantine N. Syrigos and Donald G. Skinner. 410 pp., illustrated. New York, Oxford University Press, 1999. $129.50. 0-19-263038-5 (2000) (1)
Presentation of germ cell tumors. (2003) (1)
Chemotherapy for metastatic seminoma. (2003) (1)
[Basic principles and initial results of adjuvant hormone therapy and irradiation of prostatic carcinoma]. (1997) (1)
Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped prostate cancer (1999) (1)
Intensity modulated radiation therapy. (2004) (1)
Hodgkin's disease of the liver; prognosis and possible indications for radiotherapy. (1991) (1)
A trial of carboplatin-based combination chemotherapy in good prognosis metastatic NSGCT (1994) (1)
Proffered paper non-Hodgkin's diseasePeripheral blood involvement in non-Hodgkin's lymphoma (NHL) detected by clonal gene rearrangement as a biological prognostic marker (1993) (1)
Retroperitoneal lymph-node dissection after chemotherapy for germ cell cancer in patients with elevated tumor markers (2006) (1)
A trial of accelerated fractionation (AF) in T2/3 bladder cancer (1999) (1)
Is there a volume effect for acute side-effects following pelvic radiotherapy? (1993) (1)
Factors Associated with Bleomycin Lung Toxicity in Germ Cell Tumour Patients Treated at the Royal Marsden Hospital Between 1982 and 1999 (2002) (0)
The prognostic value of PSA derivatives in favourable risk localised prostate cancer (2007) (0)
Walter & Miller's Textbook of Radiotherapy (5th edn) (1994) (0)
Intens ive Induct ion Chemotherapy With CBOP / BEP in Pat ients With Poor Prognosis Germ Cel l Tumors (2003) (0)
Stage II Seminoma and Advanced Disease (2011) (0)
Prospective phase 1 study assessing feasibility of IMRT and IGART to deliver simultaneous integrated high-dose tumor boost (up to 70 Gy) for the radical treatment of localized muscle-invasive bladder cancer. (2015) (0)
Serum tumour marker patterns, after chemotherapy for malignant germ-cell tumours, of the testis (1987) (0)
132A reanalysis of the royal marsden hospital testicular teratoma surveillance programme (1996) (0)
Book reviewsIntraoperative Radiation Therapy. Ed. by DobelbowerR. and AbeM., pp. x + 413, 1989 (CRC Press, Florida), £127.50. ISBN 0–8493–6846–4 (1991) (0)
Rituximab, gemcitabine, cisplatin, and methylprednisolone (R-GEM-P) in treatment of relapsed diffuse large B-cell lymphoma (DLBCL). (2013) (0)
Radical radiotherapy for T1 bladder cancer: The experience of the royal marsden hospital (1993) (0)
Time Course of Recovery of Serum Testosterone Following Short Course Neo Adjuvant LHRH Analogue and Radical Radiotherapy in Localised Prostate Cancer (2005) (0)
TREATMENT OF TESTICULAR TUMOURS (1983) (0)
4500 ORAL Evidence based guidelines for the follow-up of testicular cancer (2007) (0)
Editorial Conservative Treatment of Bladder Cancer (2004) (0)
The efficacy of preventing neutropenic sepsis in patients with testicular germ cell tumours: results of two consecutive audits. (2010) (0)
Optimal P lanning T arget V olume f or S tage I T esticular Seminoma: A M edical R esearch C ouncil R andomized T rial (2013) (0)
A prognostic model for response and outcome in patients with extragonadal germ cell tumors — an international multivariate analysis (2001) (0)
Management of Testicular Germ Cell Tumors (2003) (0)
Anthropomorphic and hormone abnormalities in testicular cancer patients. (2011) (0)
Salvage therapy: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. (2011) (0)
Management Strategies for Hormone-Refractory Prostate Cancer (2006) (0)
PO-0680 DOSIMETRIC COMPARISON OF FORWARD PLANNED IMRT (F-IMRT), INVERSE PLANNED IMRT (I-IMRT) AND VMAT FOR PROSTATE CANCER (2012) (0)
Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (0)
Radiotherapy and its relationship to radiobiology (1990) (0)
Corrigendum to: Pentoxifylline to Treat Radiation Proctitis: A Small and Inconclusive Randomised Trial (2008) (0)
Guidelines EAU Guidelines on Testicular Cancer : 2011 Update (2012) (0)
EP-1240: Clinical outcomes of image guided adaptive radiotherapy (IGART) for hypofractionated treatment of bladder cancer (2015) (0)
The role of F-18fluorodeoxyglucose positron emission tomography – computed tomography in the management of testicular cancers. (2015) (0)
Germ Cell Tumours (2006) (0)
One Size Doesn't Fit All: The Value of Adaptive Radiotherapy (ART) Planning Methods using Daily Image Guidance in Bladder Radiotherapy (RT) (2008) (0)
TRENDS AND SOCIO-ECONOMIC INEQUALITIES IN CANCER SURVIVAL OF PATIENTS WITH HODGKIN’S DISEASE DIAG- NOSED IN ENGLAND AND WALES BETWEEN 1986 AND 1999 (2005) (0)
Diethylstilbestrol (DES) in hormone resistant prostate cancer (HRPC): PSA response, palliative benefit and survival (2001) (0)
clinical practice guidelines Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2010) (0)
Prognostic factors in low grade NHL (A multivariate analys) (1997) (0)
Controversies in testicular cancer management. (1995) (0)
9. Hydralazine increases blood flow through human lung tumours (1990) (0)
671Bilateral germ cell tumours of the testis (2005) (0)
4004 ORAL Avoiding overtreatment of prostate cancer: optimising patient selection for active surveillance (2007) (0)
No Beyer et al consensus Ann Oncol 2012 (2012) (0)
Multivariate Analysis of Predictive Factors of Late Relapse in 1264 Patients with Testicular Germ Cell Tumours (2002) (0)
4511 POSTER Selective organ preservation in muscle-invasive transitional cell carcinoma of the bladder: Pilot study for a randomised phase III trial (2007) (0)
Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience (2018) (0)
Re: Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. G. J. Fellows et al. Br. J. Urol., 70, 304-309, 1992. (1993) (0)
928: Bone Metastases from Testicular Tumours: Management and Outcomes (2004) (0)
Basic principles of clinical trials as applied to testicular cancer. (1990) (0)
Management of germ cell tumours of the testis (1999) (0)
Autologous peripheral blood stem cell rescue permits administration of high activities of rhenium-186 HEDP in progressive hormone refractory prostate cancer metastatic to bone (2002) (0)
Stage I Testicular Non Seminoma (2011) (0)
7183 Outcomes in metastatic (met) germ cell tumours (GCT): 5-year experience from a single institution (2009) (0)
Identification and Management of High Risk Testicular Germ Cell Tumours: Conclusions, Perspectives and Closing Remarks (1993) (0)
Reply: Seminoma stage 1: Patterns of care in Europe. (2013) (0)
Cardiovascular D isease a s a L ong-Term C omplication o f Treatment f or T esticular C ancer (2003) (0)
Genitourinary cancers (2019) (0)
Fertility and Quality of Life after Treatment for Testicular Cancer (2002) (0)
EUROPEAN ASSOCIATION OF UROLOGY (2006) (0)
Diagnosis and treatment of urological malignancy: the testes. (1996) (0)
LOW TOXICITY PLATINUM COMBINATION CHEMOTHERAPY (PMO) FOR UROTHELIAL CANCER (1990) (0)
appendix 8: Prostate cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Genitourinary-Cancers). (2016) (0)
Reply (2013) (0)
Seminoma stage 1: Patterns of care in Europe Reply (2013) (0)
CARBOPLATIN DOSE DETERMINATION USING A SIMPLE FORMULA - SINGLE AGENT, COMBINATION AND HIGH-DOSE STUDIES (1989) (0)
Surveillance for low-stage testicular germ cell cancers (2006) (0)
British Association for Cancer Research/Association of Cancer Physicians/British Oncological Association/Joint Symposium on `Radiotherapy - 100 Years On' (incorporating the 1995 Gordon Hamilton-Fairley Memorial Lecture), 'The Tumour and its Environment' and 'Whither High Dose Chemotherapy?' and BACR (1996) (0)
Chapter 8 The role of bisphosphonates in the systemic treatment of prostate cancer (2010) (0)
Autologous bone marrow transplantation and radiotherapy in patients with Hodgkin's disease (1993) (0)
Low Dose Rate in Clinical Radiotherapy (1988) (0)
Adjuvant treatments for locally advanced prostate cancer. (2011) (0)
Management strategies for prostate cancer (2006) (0)
CHAPTER 14 – Germ cell tumors (2009) (0)
High Dose Chemotherapy with Haemopoietic Stem Cell Support (1994) (0)
Risk o f S econd M alignancy A fter H odgkin's D isease i n a Collaborative B ritish C ohort: T he R elation t o A ge a t T reatment (2000) (0)
Intensive I nduction C hemotherapy W ith C BOP/BEP i n P atients With P oor P rognosis G erm C ell T umors (2003) (0)
GONADOTROPIN AND SEX-HORMONE LEVELS IN TESTIS CANCER-PATIENTS WITH AND WITHOUT CARCINOMA IN-SITU OF THE CONTRALATERAL TESTIS (1994) (0)
Adjuvant chemotherapy for high-risk low-stage germ-cell tumours (2002) (0)
Paper429-07 feb 1998 (1998) (0)
Benefit of radiotherapy dose escalation in localized prostate cancer with respect to expression of intrinsic markers of hypoxia. (2009) (0)
Haematological malignancies (Chapter 27) (2002) (0)
The relative risk of secondary tumors in extragonadal germ cell tumors (EGGCT) (1999) (0)
High activity rhenium-186 HEDP with peripheral blood stem cell support -a novel approach to hormone refractory prostate cancer metastatic to bone (2001) (0)
902 Optimal field size in adjuvant treatment of stage I seminoma (1995) (0)
A report of the 13 cases of primary small cell carcinoma of the urinary bladder: The Royal Marsden Hospital experience. (2001) (0)
Carboplatin based chemotherapy in the treatment of advanced urothelial cancer with poor prognostic features. (2002) (0)
Evaluating the Relationship Between Erectile Dysfunction and Dose Received by the Penile Bulb in Patients Undergoing Conformal Radiotherapy for Prostate Cancer: Analysis of Data From the MRC RT01 Dose Escalation Trial (ISRCTN47772397) (2005) (0)
The Impact of Hydronephrosis on Renal Function in Patients Treated with Cisplatin-Based Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumors (1989) (0)
The role of radiotherapy in non-Hodgkin's lymphoma. (2004) (0)
21. Role of PET imaging with 18F-deoxyglucose (18F-FDG) in the management of testicular germ cell tumours (1994) (0)
Is apoptosis an important mode of death in embryonal carcinoma (1994) (0)
4501 ORAL Long term neurological and peripheral vascular toxicity following chemotherapy treatment of testicular cancer (2007) (0)
Management of extragonadal seminoma (EG-SEM) — Results of a multicenter analysis of 104 patients (PTS) (1999) (0)
Conservative treatment of bladder cancer. (2004) (0)
236Hypofractionated radiotherapy for primary carcinoma of the bladder in geriatric patients (1996) (0)
Immunological investigation of lymphoid neoplasms, G. T. Stevenson, J. L. Smith, T. J. Hamblin, Churchill Livingstone, Edinburgh, London, Melbourne and New York, 1983. No. of pages: i–xi + 91 (incl. index). Price: £18.00. ISBN 0 443 02452 9 (1984) (0)
23 Stage 1 testicular germ cell cancers (2011) (0)
Testicular germ cell tumours and contralateral CIS: British Medical Research Council study. (1996) (0)
Dosimetric comparison of forward planned IMRT (F-IMRT), inverse planned IMRT (I-IMRT) and VMAT for p (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alan H. Horwich?

Alan H. Horwich is affiliated with the following schools:

Institute of Cancer Research